tacrolimus and Acne-Vulgaris

tacrolimus has been researched along with Acne-Vulgaris* in 7 studies

Other Studies

7 other study(ies) available for tacrolimus and Acne-Vulgaris

ArticleYear
Topical tacrolimus for acne-related macular erythema to prevent atrophic scarring.
    Journal of the American Academy of Dermatology, 2022, Volume: 86, Issue:6

    Topics: Acne Vulgaris; Atrophy; Cicatrix; Connective Tissue Diseases; Erythema; Humans; Tacrolimus; Treatment Outcome

2022
Successful Treatment of PAPA Syndrome with Dual Adalimumab and Tacrolimus Therapy.
    Journal of clinical immunology, 2019, Volume: 39, Issue:8

    Topics: Acne Vulgaris; Adalimumab; Arthritis, Infectious; Child; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Pyoderma Gangrenosum; Tacrolimus; Treatment Outcome

2019
Facial acne during topical pimecrolimus therapy for vitiligo.
    Clinical and experimental dermatology, 2009, Volume: 34, Issue:7

    Topics: Acne Vulgaris; Adolescent; Dermatologic Agents; Drug Eruptions; Humans; Male; Tacrolimus; Vitiligo

2009
Focal acne during topical tacrolimus therapy for vitiligo.
    Archives of dermatology, 2007, Volume: 143, Issue:9

    Topics: Acne Vulgaris; Adolescent; Facial Dermatoses; Female; Humans; Immunosuppressive Agents; Tacrolimus; Vitiligo

2007
Randomized controlled trial of pimecrolimus 1% cream for treatment of facial acne vulgaris.
    Journal of the American Academy of Dermatology, 2005, Volume: 52, Issue:4

    Topics: Acne Vulgaris; Adolescent; Chemistry, Pharmaceutical; Child; Double-Blind Method; Female; Humans; Immunosuppressive Agents; Male; Pilot Projects; Tacrolimus

2005
Are we starting to induce skin cancer in order to avoid topical steroids?
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2005, Volume: 19, Issue:3

    Topics: Acne Vulgaris; Animals; Child; Humans; Immunosuppressive Agents; Mice; Mice, Hairless; Skin Neoplasms; Steroids; Tacrolimus

2005
Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment.
    Archives of dermatology, 2004, Volume: 140, Issue:4

    Tacrolimus ointment is increasingly used for anti-inflammatory treatment of sensitive areas such as the face, and recent observations indicate that the treatment is effective in steroid-aggravated rosacea and perioral dermatitis. We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment.. Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments. Within 2 to 3 weeks of initially effective and well-tolerated treatment, 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions. Biopsy revealed an abundance of Demodex mites in 2 of these patients. In 1 patient with eyelid eczema, rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment. In 1 patient with atopic dermatitis, telangiectatic and papular rosacea insidiously appeared after 5 months of treatment.. Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous. A variety of factors, such as vasoactive properties of tacrolimus, proliferation of Demodex due to local immunosuppression, and the occlusive properties of the ointment, may be involved in the observed phenomena. Future studies are needed to identify individual risk factors.

    Topics: Acne Vulgaris; Administration, Topical; Adult; Dermatitis, Atopic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Ointments; Risk Assessment; Rosacea; Sampling Studies; Severity of Illness Index; Tacrolimus

2004